# Becton, Dickinson and Company (BDX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $42.64B  
**Price:** $147.79 (-2.80%)

> Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare systems and research institutions worldwide. Its portfolio includes medical surgical products such as needles, syringes, and sharps-disposal units, as well as prefilled drug delivery systems that support medication administration in clinical and home-care settings. In diagnostics and life sciences, the company provides instruments, reagents, and systems used for specimen collection, infectious disease testing, and advanced cell analysis, including flow cytometry and cell-imaging platforms. Becton, Dickinson and Company operates through distinct business segments that address medication management, life science research, and interventional therapies, serving hospitals, clinics, laboratories, and biopharmaceutical companies. Headquartered in Franklin Lakes, New Jersey, and founded in 1897, it plays a significant role in supporting healthcare delivery and laboratory workflows across both developed and emerging markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $21.84B | $9.93B | $2.58B | $1.68B | — |
| 2024 | $20.18B | $9.13B | $2.40B | $1.71B | — |
| 2023 | $19.37B | $8.17B | $2.11B | $1.48B | — |
| 2022 | $18.87B | $8.48B | $2.28B | $1.78B | — |
| 2021 | $19.13B | $8.63B | $2.25B | $2.09B | — |
| 2020 | $16.07B | $7.58B | $912M | $874M | — |
| 2019 | $17.29B | $8.29B | $1.76B | $1.23B | — |
| 2018 | $15.98B | $7.26B | $1.51B | $311M | — |
| 2017 | $12.09B | $5.94B | $1.52B | $1.10B | — |
| 2016 | $12.48B | $5.99B | $1.43B | $976M | — |
| 2015 | $10.28B | $4.70B | $1.07B | $695M | — |
| 2014 | $8.45B | $4.30B | $1.61B | $1.19B | — |
| 2013 | $8.05B | $4.17B | $1.25B | $1.29B | — |
| 2012 | $7.71B | $3.95B | $1.56B | $1.17B | — |
| 2011 | $7.58B | $3.96B | $1.67B | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $55.33B | $29.93B | $25.39B | $567M | $17.62B |
| 2024 | $57.29B | $31.40B | $25.89B | $1.72B | $17.94B |
| 2023 | $52.78B | $26.98B | $25.80B | $1.42B | $14.74B |
| 2022 | $52.93B | $27.65B | $25.28B | $1.01B | $13.89B |
| 2021 | $53.87B | $30.19B | $23.68B | $2.28B | $17.11B |
| 2020 | $54.01B | $30.25B | $23.77B | $2.83B | $17.22B |
| 2019 | $51.77B | $30.68B | $21.08B | $536M | $18.08B |
| 2018 | $53.90B | $32.91B | $20.99B | $1.14B | $18.89B |
| 2017 | $37.73B | $24.79B | $12.95B | $14.18B | $18.67B |
| 2016 | $25.59B | $17.95B | $7.63B | $1.54B | $10.55B |
| 2015 | $26.48B | $19.31B | $7.16B | $1.42B | $11.37B |
| 2014 | $12.38B | $7.33B | $5.05B | $1.86B | $3.77B |
| 2013 | $12.15B | $7.11B | $5.04B | $1.89B | $3.76B |
| 2012 | $11.36B | $7.22B | $4.14B | $1.67B | $3.76B |
| 2011 | $10.43B | $5.60B | $4.83B | $1.18B | $2.48B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2021 | $4.65B | $1.19B | $3.45B |
| 2020 | $3.54B | $769M | $2.77B |
| 2019 | $3.33B | $957M | $2.37B |
| 2018 | $2.87B | $895M | $1.97B |
| 2017 | $2.55B | $727M | $1.82B |
| 2016 | $2.56B | $693M | $1.87B |
| 2015 | $1.73B | $596M | $1.13B |
| 2014 | $1.75B | $592M | $1.15B |

Source: [CompaniesByCap](https://companiesbycap.com/company/BDX)